Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

721

Enrollment

INDUSTRY

Sponsor class

Conditions

Graft Rejection

Interventions

DRUG: everolimus
DRUG: mycophenolate mofetil
DRUG: cyclosporine
DRUG: corticosteroids

Sponsor

Novartis Pharmaceuticals